登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>PVRIG >PVG-H52H4

Human PVRIG Protein, His Tag

分子别名(Synonym)

C7orf15,C7orf15MGC138295,CD112R,MGC104322,MGC138297,MGC2463,PVRIG,CD112 receptor

表达区间及表达系统(Source)

Human PVRIG, His Tag (PVG-H52H4) is expressed from human 293 cells (HEK293). It contains AA Thr 41 - Asp 171 (Accession # Q6DKI7-1).

Predicted N-terminus: Thr 41

Request for sequence

蛋白结构(Molecular Characterization)

PVRIG Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 15.6 kDa. The protein migrates as 20-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

PVRIG SDS-PAGE

Human PVRIG, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

PVRIG ELISA

Immobilized Human PVRIG, His Tag (Cat. No. PVG-H52H4) at 2 μg/mL (100 μL/well) can bind Human Nectin-2, Fc Tag (Cat. No. PV2-H5253) with a linear range of 0.5-8 ng/mL (QC tested).

Protocol

PVRIG ELISA

Immobilized Biotinylated Human Nectin-2, Fc,Avitag (Cat. No. CD2-H82F8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Human PVRIG, His Tag (Cat. No. PVG-H52H4) with a linear range of 1-39 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

PVRIG BLI

Loaded Human Nectin-2, Fc Tag (Cat. No. PV2-H5253) on Protein A Biosensor, can bind Human PVRIG, His Tag (Cat. No. PVG-H52H4) with an affinity constant of 0.456 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 
评论(3)
  1. 136XXXXXXX0
  2. 1人赞
  3. 大量购买该产品,质量很好。作为免疫原,可以得到较高的滴度,作为ELISA筛选用抗原,也可以很好地与目的抗体结合。已经通过该蛋白,免疫,筛选得等很好的抗体。
  4. >
  5. 2022-10-28
  1. 156XXXXXXX8
  2. 0人赞
  3. 我们采购人的CD112R-His标签的蛋白,主要是用于筛选抗CD112R的药用抗体分子。前期用于小鼠的动物免疫和后期的ELISA筛选上,目前选用该蛋白免疫的小鼠在三次免疫之后均达到了融合要求,后面将用该蛋白进行阳性杂交瘤的初筛。
  4. 2022-4-6
  1. 158XXXXXXX0
  2. 0人赞
  3. 我们2022年一个项目是中美双报的,ACRO检测数据已经经受住了FDA的考验。新项目毫不犹豫还是选择ACRO,性价比高,抗体稳定性好,值得推荐!
  4. 2022-12-22
 
ACRO质量管理体系
 
 

背景(Background)

Human PVRIG (poliovirus receptor related immunoglobulin domain-containing protein), also known as CD112 receptor (CD112R), is an approximately 34 kDa single transmembrane protein in the poliovirus receptor-like protein (PVR) family. The CD112R gene encodes a putative single transmembrane protein, which is composed of a single extracellular IgV domain, one transmembrane domain, and a long intracellular domain. Notably, the intracellular domain of phatases. The extracellular domain sequence of human and mouse CD112R have 65.3% similarity. CD112R may act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals.

 

前沿进展

Co-blocking TIGIT and PVRIG using a novel bispecific antibody enhances anti-tumor immunity
Lin, Lin, Fu et al
Mol Cancer Ther (2025)
Abstract: TIGIT and PVRIG are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as promising dual targets for cancer immunotherapy. This study aimed to develop a bispecific antibody (BsAb) to co-target TIGIT and PVRIG. Expression of TIGIT and PVRIG was assessed on tumor-infiltrating lymphocytes (TILs) from patients with various cancers, including non-small cell lung cancer (n=63) and colorectal cancer (n=26). The BsAb was engineered by fusing anti-PVRIG nanobodies to the N terminus of anti-TIGIT antibodies. Functional characterization of the BsAb was performed in vitro and in vivo, including assessments of T and NK cell activation and cytotoxicity. Pharmacokinetics and safety profiles were evaluated in cynomolgus monkeys. Statistical analyses were conducted using the Student's t-test. The results showed that the BsAb effectively blocked TIGIT and PVRIG from binding their respective ligands, CD155 and CD112, leading to significant increases in T cell activation (2.8-fold, p<0.05) and NK cell cytotoxicity (1.8-fold, p<0.05). In vivo, the BsAb demonstrated potent anti-tumor activity, both as a monotherapy and in combination with anti-PD-1 or anti-PD-L1, in humanized PBMC and transgenic mouse models. Pharmacokinetic studies in cynomolgus monkeys revealed a favorable profile, with no dose-limiting toxicities observed after four repeated doses of 200 mg/kg. These findings provide compelling preclinical evidence for the therapeutic potential of targeting the TIGIT-PVRIG axis with a bispecific antibody. This approach shows promise for enhancing anti-tumor immunity and warrants further investigation in clinical trials.
The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation
Frenkel, Alteber, Xu et al
Exp Hematol (2025) 143, 104696
Abstract: Therapeutic advances in treating patients with multiple myeloma (MM), including novel immunotherapies, have improved the disease control, but it remains incurable. Although traditional immune check point inhibitors have shown limited clinical benefit, targeting alternative immune-inhibitory pathways may offer a novel way to address relapsed disease. Blockade of the immune regulator TIGIT was shown to enhance antitumor immunity in preclinical MM models. Beyond TIGIT, the DNAM-1 axis includes the novel inhibitory receptor PVR related immunoglobulin (PVRIG). In this study we evaluated the expression of DNAM-1 axis receptors and the function of PVRIG in bone marrow of individuals with MM, specifically highlighting PVRIG blockade as a potential therapeutic opportunity in combination with bispecific T-cell engager (BiTE).Copyright © 2024 International Society for Experimental Hematology. All rights reserved.
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer
Connor, Lyons, Kilgallon et al
Heliyon (2024) 10 (20), e38888
Abstract: The 5-year survival rate for ovarian cancer has remained relatively static over the past number of years, which can be attributed in part to the lack of new therapeutic strategies to target this disease. Although numerous other cancer types have benefited from the success of immune checkpoint inhibitors, their use in clinical trials targeting ovarian cancer has shown limited efficacy. Most clinical trials have focused on PD-1/PD-L1 immune checkpoint blockade, either as a monotherapy or in combination with chemotherapies, however inhibiting other pathways may potentially be more efficacious in treating ovarian cancer. For example, drugs targeting some emerging immune checkpoints (such as LAG-3, TIM-3, TIGIT and PVRIG), are entering into clinical trials, which could show improved success for ovarian cancer patients. Similarly, predictive biomarkers that have been approved for use with immune checkpoint inhibitors, such as PD-L1 expression, are limited, as only the presence or absence of PD-L1 is assessed. However, the development of next generation predictive biomarkers, which assesses density and location of tumour infiltrating lymphocytes, could be more beneficial for this heterogenous cancer. In this review we discuss the use of immune checkpoint inhibitors in ovarian cancer, with a focus on high-grade serous disease, and delve into what the future may hold for immunotherapy in this cancer type.© 2024 Published by Elsevier Ltd.
Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity
Nihtilä, Penna, Salmenniemi et al
Sci Rep (2024) 14 (1), 26988
Abstract: Natural killer (NK) cells recognize and may kill malignant cells via their cell surface receptors. Killer cell immunoglobulin-like receptor (KIR) genotypes of donors have been reported to adjust the risk of relapse after allogeneic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia. To test whether non-KIR NK cell receptors have a similar effect, we screened 1,638 genetic polymorphisms in 21 non-KIR NK cell receptor genes for their associations with relapse and graft-versus-host disease (GVHD) after HSCT in 1,491 HSCT donors (from Finland, the UK, Spain, and Poland), divided into a discovery and replication cohort. Eleven polymorphisms regulating or located in CD226, CD244, FCGR3A, KLRD1, NCR3, and PVRIG were associated with the risks for relapse and GVHD. These associations could not be confirmed in the replication cohort. Blood donor NK cells carrying alleles showing genetic protection for relapse had a higher in vitro NK cell killing activity than non-carriers whereas those with alleles genetically protective for GVHD had lower cytotoxicity, potentially indicating functional effects. Taken together, these results show no robust effects of genetic variation in the tested non-KIR NK cell receptors on the outcome of HSCT.© 2024. The Author(s).
Showing 1-4 of 40 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
PVRIG靶点信息
英文全称:Transmembrane protein PVRIG
中文全称:跨膜蛋白PVRIG
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:7详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定